IRIS
NAPOLITANO, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.555
NA - Nord America 1.268
AS - Asia 340
SA - Sud America 3
AF - Africa 1
OC - Oceania 1
Totale 3.168
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.246
IE - Irlanda 596
IT - Italia 415
DE - Germania 171
SG - Singapore 162
GB - Regno Unito 100
CN - Cina 91
UA - Ucraina 65
FR - Francia 53
SE - Svezia 40
GR - Grecia 31
FI - Finlandia 27
KR - Corea 25
TR - Turchia 22
CA - Canada 20
CZ - Repubblica Ceca 17
PK - Pakistan 14
BE - Belgio 12
NL - Olanda 11
IN - India 9
VN - Vietnam 6
ES - Italia 5
AT - Austria 4
MK - Macedonia 3
GI - Gibilterra 2
HK - Hong Kong 2
IR - Iran 2
MX - Messico 2
TW - Taiwan 2
AR - Argentina 1
AU - Australia 1
BD - Bangladesh 1
BG - Bulgaria 1
BO - Bolivia 1
BW - Botswana 1
HU - Ungheria 1
JP - Giappone 1
KG - Kirghizistan 1
LK - Sri Lanka 1
PE - Perù 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 3.168
Salva come PNG Salva come JPEG
Città #
Dublin 582
Chandler 282
Jacksonville 108
Singapore 103
Naples 101
Santa Clara 101
New York 72
Bremen 68
Princeton 66
Roxbury 66
Munich 46
Caserta 39
Beijing 38
Cambridge 37
Ann Arbor 33
Medford 29
Seoul 25
Wilmington 20
Milan 19
Brno 16
Elora 16
Ashburn 15
Boardman 14
Des Moines 14
Los Angeles 14
Napoli 13
Brussels 12
Rome 12
Woodbridge 12
Lappeenranta 10
Houston 9
San Mateo 9
Amsterdam 6
Dong Ket 6
Helsinki 6
Istanbul 6
Jinan 6
Nanjing 6
Pozzuoli 6
Rimini 6
Bahawalpur 5
Battipaglia 5
Düsseldorf 5
Menlo Park 5
Mountain View 5
Anantapur 4
Ercolano 4
Fairfield 4
Toronto 4
Vienna 4
Auburn Hills 3
Colle di Val d'Elsa 3
Madrid 3
Montecorvino Rovella 3
Montpellier 3
Nanchang 3
Norwalk 3
Sennori 3
Venice 3
Viareggio 3
Acerra 2
Alba Adriatica 2
Andover 2
Avellino 2
Berlin 2
Castellammare di Stabia 2
Castello di Brianza 2
Cinquevie 2
Corbara 2
Florence 2
Groningen 2
Gunzenhausen 2
Matera 2
Mexico 2
Molinella 2
Nola 2
Pune 2
San Nicola la Strada 2
Sant Antoni de Portmany 2
Seattle 2
Shanghai 2
Shenyang 2
Skopje 2
Strasbourg 2
Tainan City 2
Taiyuan 2
Antea 1
Aversa 1
Bangkok 1
Baoding 1
Bari 1
Bedizzole 1
Benevento 1
Bezons 1
Bishkek 1
Bratislava 1
Castellammare Di Stabia 1
Catania 1
Central 1
Cercola 1
Totale 2.190
Salva come PNG Salva come JPEG
Nome #
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 103
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 87
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 81
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 80
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 70
AXL is an oncotarget in human colorectal cancer 67
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 64
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 63
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 60
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 60
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 59
Beyond N staging in colorectal cancer: Current approaches and future perspectives 58
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 56
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 54
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 52
It is finally time for adjuvant therapy in melanoma 49
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 49
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 49
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 49
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 47
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 46
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 45
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 45
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 44
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 42
PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples 42
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 42
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 41
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 41
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 40
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 40
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 40
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 40
Treatment of cutaneous melanoma harboring smo p.Gln216arg mutation with imiquimod: An old drug with new results 39
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma 39
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 38
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 38
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 38
Immunotherapy for head and neck cancer: Present and future 38
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 37
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 37
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 37
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 37
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 36
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 36
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 35
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 34
Clinical management of metastatic colorectal cancer in the era of precision medicine 34
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 33
Novel in vitro cancer models for optimizing anti- EGFR therapies 33
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 33
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 32
The Role of Sentinel Node Biopsy in the Era of Adjuvant Therapy for Melanoma 32
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression 31
Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy 31
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models 29
Pimasertib hydrochloride 29
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 28
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 27
Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge 27
Current Landscape and Open Questions on Adjuvant Therapies in Melanoma 26
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 25
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 24
How we treat metastatic colorectal cancer 24
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 24
Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era 23
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 22
Towards the era of precision medicine in metastatic colorectal cancer 21
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 21
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 20
NMR profiling of Ononis diffusa identifies cytotoxic compounds against cetuximab-resistant colon cancer cell lines 20
Hypothalamic–pituitary autoimmunity in patients treated with anti-pd-1 and anti-pd-l1 antibodies 20
Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer 20
Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review 19
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 19
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 19
Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review 18
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data 18
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment 18
"RT STRIKES BACK": Radiotherapy in Ultra Elderly with Cutaneous Basal Cell Carcinoma 17
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. 17
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 16
Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer 15
Mechanisms of innate and acquired resistance to anti-EGFR therapy: A review of current knowledge with a focus on rechallenge therapies 15
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 14
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 13
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 12
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 12
The Role of Adjuvant Therapy for the Treatment of Micrometastases in Endometrial Cancer: A Systematic Review and Meta-Analysis 10
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 10
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy 8
A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors 7
MicroRNA Expression in Endometrial Cancer: Current Knowledge and Therapeutic Implications 7
Sentinel node biopsy in thin melanoma: a retrospective descriptive cohort study 7
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 6
Magnetic Resonance Imaging Evaluation of Bone Metastases Treated with Radiotherapy in Palliative Intent: A Multicenter Prospective Study on Clinical and Instrumental Evaluation Assessment Concordance (MARTE Study) 6
Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis 5
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 5
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 5
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma 5
Totale 3.336
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.095
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.095
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020135 0 0 0 0 16 6 34 10 27 26 12 4
2020/2021256 28 11 18 20 23 13 25 23 12 29 38 16
2021/2022514 15 13 6 4 105 15 38 15 30 59 64 150
2022/20231.193 127 18 32 96 149 97 5 66 545 9 33 16
2023/2024596 61 25 17 23 158 88 18 22 18 14 54 98
2024/2025428 52 53 30 98 195 0 0 0 0 0 0 0
Totale 3.366